Financials data is unavailable for this security.
View more
Year on year Viridian Therapeutics Inc 's revenues fell -82.28% from 1.77m to 314.00k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 129.87m to a larger loss of 237.73m.
Gross margin | -- |
---|---|
Net profit margin | -75,737.84% |
Operating margin | -82,595.14% |
Return on assets | -42.89% |
---|---|
Return on equity | -72.90% |
Return on investment | -45.38% |
More ▼
Cash flow in USDView more
SmartText is unavailable
Cash flow per share | -4.40 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 9.13 |
---|---|
Tangible book value per share | 9.13 |
More ▼
Balance sheet in USDView more
Current ratio | 23.99 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0349 |
---|---|
Total debt/total capital | 0.0337 |
More ▼